NCT06127355View on ClinicalTrials.gov

Gestational Treatment With Ursodeoxycholic Acid Compared to Placebo to Reduce Severity of Gestational Diabetes Mellitus Diagnosed at 24-28 Weeks' Gestation

PHASE3CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

February 9, 2022

Study Completion Date

May 10, 2022

Conditions
Gestational Diabetes
Interventions
DRUG

500 mg of ursodeoxycholic acid (UDCA)

Administration of 500 mg of ursodeoxycholic acid (UDCA) /day

OTHER

500 mg of Placebo

Administration of 500 mg of placebo /day

Trial Locations (1)

30120

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

All Listed Sponsors
lead

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

OTHER

NCT06127355 - Gestational Treatment With Ursodeoxycholic Acid Compared to Placebo to Reduce Severity of Gestational Diabetes Mellitus Diagnosed at 24-28 Weeks' Gestation | Biotech Hunter | Biotech Hunter